scholarly article | Q13442814 |
P2093 | author name string | H. Fukui | |
S. Terada | |||
I. Tanaka | |||
A. Yoshioka | |||
H. Nakai | |||
M. Shima | |||
D. Scandella | |||
S. Kamisue | |||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | monoclonal antibody | Q422248 |
P304 | page(s) | 240-246 | |
P577 | publication date | 1993-03-01 | |
P1433 | published in | Thrombosis and Haemostasis | Q15724413 |
P1476 | title | A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine | |
P478 | volume | 69 |
Q36250957 | A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function |
Q36447889 | Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation |
Q37382199 | B-cell and T-cell epitopes in anti-factor VIII immune responses |
Q42036652 | Binding of blood coagulation factor VIII and its light chain to phosphatidylserine/phosphatidylcholine bilayers as measured by ellipsometry. |
Q38118763 | Blood Clotting Factor VIII: From Evolution to Therapy |
Q36742268 | Characterization and solution structure of the factor VIII C2 domain in a ternary complex with classical and non-classical inhibitor antibodies |
Q36412125 | Characterization of factor VIII inhibitors |
Q37626483 | Epitope mapping of inhibitory antibodies targeting the C2 domain of coagulation factor VIII by hydrogen-deuterium exchange mass spectrometry. |
Q33918888 | Haemophilia A and haemophilia B: molecular insights |
Q53315892 | Haemophilia A and haemophilia B: molecular insights. |
Q36317966 | Highly conserved antigenic structure of the factor VIII C2 domain in some mammals. |
Q43167061 | Identification of plasmin-interactive sites in the light chain of factor VIII responsible for proteolytic cleavage at Lys36. |
Q82712834 | Management of factor VIII inhibitors |
Q37382208 | Management of haemophilia A-inhibitor patients: clinical and regulatory perspectives |
Q41850873 | Mapping the interaction between factor VIII and von Willebrand factor by electron microscopy and mass spectrometry |
Q36896861 | Membrane-binding properties of the Factor VIII C2 domain |
Q33962546 | Non-classical anti-factor VIII C2 domain antibodies are pathogenic in a murine in vivo bleeding model. |
Q36835121 | Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors |
Q64067191 | Peptides identified on monocyte-derived dendritic cells: a marker for clinical immunogenicity to FVIII products |
Q37129689 | Quantitation of anti-factor VIII antibodies in human plasma |
Q80273707 | Relationship between the binding sites for von Willebrand factor, phospholipid, and human factor VIII C2 inhibitor alloantibodies within the factor VIII C2 domain |
Q24530891 | Structure and topography of the membrane-binding C2 domain of factor VIII in the presence of dodecylphosphocholine micelles |
Q36310238 | Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody |
Q27680123 | Structure of the factor VIII C2 domain in a ternary complex with 2 inhibitor antibodies reveals classical and nonclassical epitopes |
Q35578480 | The 1.7 Å X-ray crystal structure of the porcine factor VIII C2 domain and binding analysis to anti-human C2 domain antibodies and phospholipid surfaces |
Q35832756 | The important role of von Willebrand factor in platelet-derived FVIII gene therapy for murine hemophilia A in the presence of inhibitory antibodies. |
Q45866649 | The structural basis for the functional comparability of factor VIII and the long-acting variant recombinant factor VIII Fc fusion protein |
Q37374547 | Varied immune response to FVIII: presence of proteolytic antibodies directed to factor VIII in different human pathologies |
Search more.